Show simple item record

AuthorEssa, Asma
AuthorAldous, Noura
AuthorBenslimane, Fatiha
AuthorYalcin, Huseyin
Available date2020-10-26T08:49:56Z
Publication Date2020
Publication NameQatar University Annual Research an Exhibition 2020 (quarfe)
CitationEssa A., Aldous N., Benslimane F., Yalcin H., "In Vivo Investigation of Cardiac Benefits of Sodium Glucose Cotransporter Inhibition Using the Zebrafish Model", Qatar University Annual Research Forum and Exhibition (QUARFE 2020), Doha, 2020, https://doi.org/10.29117/quarfe.2020.0199
URIhttps://doi.org/10.29117/quarfe.2020.0199
URIhttp://hdl.handle.net/10576/16782
AbstractType 2 diabetes mellitus (T2DM) affects >16% of adults in Qatar. Newly emerging class of antidiabetic drugs focuses on SGLT inhibition were observed to reduce CVDs risks in diabetic patients. Up to date, the mechanism contributing to the CV benefits remains unrevealed. Zebrafish embryos were injected with different morpholinos to knockdown SGLT genes and study their effects on cardiac parameters. SGLT1 inhibition caused the most severe effects on zebrafish embryos with survival rate ~10 %. It also caused tube-like structured heats with edema, affecting significantly the cardiac output and diameter, and increased cardiac markers expressions. Analysis acquired correlates with literature data of SGLT1 predominant expression in heart tissues
Languageen
PublisherQatar University Press
SubjectT2DM
CVDs
Zebrafish
TitleIn Vivo Investigation of Cardiac Benefits of Sodium Glucose Cotransporter Inhibition Using the Zebrafish Model
TypePoster
dc.accessType Open Access


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record